

Chris Brown

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8381111/publications.pdf>

Version: 2024-02-01

48
papers

2,999
citations

236833

25
h-index

243529

44
g-index

49
all docs

49
docs citations

49
times ranked

4248
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey. <i>Supportive Care in Cancer</i> , 2022, 30, 511-519.	1.0	12
2	Early Outcomes and Decision Regret Using PSMA/MRI-Guided Focal Boost for Prostate Cancer SBRT. <i>Practical Radiation Oncology</i> , 2022, 12, e201-e206.	1.1	8
3	Protocol of DREAM3R: DuRvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—a phase 3 randomised trial. <i>BMJ Open</i> , 2022, 12, e057663.	0.8	9
4	Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region following radiotherapy. <i>BMC Neurology</i> , 2022, 22, 24.	0.8	2
5	Evaluating the utility of knowledge-based planning for clinical trials using the TROG 08.03 post prostatectomy radiation therapy planning data. <i>Physics and Imaging in Radiation Oncology</i> , 2022, 22, 91-97.	1.2	1
6	Scanxiety: a scoping review about scan-associated anxiety. <i>BMJ Open</i> , 2021, 11, e043215.	0.8	40
7	Experiences with scans and scanxiety in people with advanced cancer: a qualitative study. <i>Supportive Care in Cancer</i> , 2021, 29, 7441-7449.	1.0	12
8	Improving efficiency in the radiation management of multiple brain metastases using a knowledge-based planning solution for single-isocentre volumetric modulated arc therapy (VMAT) technique. <i>Journal of Medical Radiation Sciences</i> , 2021, 68, 364-370.	0.8	2
9	Assessing ISUP prostate cancer grade groups in patients treated with definitive dose escalated external beam radiation. <i>Radiotherapy and Oncology</i> , 2021, 162, 91-97.	0.3	3
10	Nutritional status and skeletal muscle status in patients with head and neck cancer: Impact on outcomes. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 2187-2198.	2.9	30
11	Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 31-39.	1.0	6
12	Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 2020, 21, 1331-1340.	5.1	197
13	Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. <i>Lancet, The</i> , 2020, 396, 1422-1431.	6.3	224
14	The Effects of Acupuncture on Cancer-Related Fatigue: Updated Systematic Review and Meta-Analysis. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473542094967.	0.8	30
15	Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1172-1178.	0.4	36
16	Rolling out RapidPlan: What we've learnt. <i>Journal of Medical Radiation Sciences</i> , 2020, 67, 310-317.	0.8	2
17	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. <i>Lancet Oncology, The</i> , 2020, 21, 1213-1223.	5.1	109
18	Best Evidence to Best Practice: Implementing an Innovative Model of Nutrition Care for Patients with Head and Neck Cancer Improves Outcomes. <i>Nutrients</i> , 2020, 12, 1465.	1.7	23

#	ARTICLE	IF	CITATIONS
19	Sarcopenia and myosteatosis in patients undergoing curative radiotherapy for head and neck cancer: Impact on survival, treatment completion, hospital admission and cost. <i>Journal of Human Nutrition and Dietetics</i> , 2020, 33, 811-821.	1.3	28
20	Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated?. <i>ANZ Journal of Surgery</i> , 2018, 88, 870-875.	0.3	5
21	Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. <i>European Urology Oncology</i> , 2018, 1, 531-537.	2.6	106
22	Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial. <i>European Journal of Cancer</i> , 2015, 51, 352-358.	1.3	40
23	Rates of obstetric intervention and associated perinatal mortality and morbidity among low-risk women giving birth in private and public hospitals in NSW (2000-2008): a linked data population-based cohort study. <i>BMJ Open</i> , 2014, 4, e004551.	0.8	47
24	Risk of recurrence, subsequent mode of birth and morbidity for women who experienced severe perineal trauma in a first birth in New South Wales between 2000 -2008: a population based data linkage study. <i>BMC Pregnancy and Childbirth</i> , 2013, 13, 89.	0.9	34
25	A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. <i>Annals of Oncology</i> , 2013, 24, 937-943.	0.6	32
26	A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. <i>Lung Cancer</i> , 2013, 81, 422-427.	0.9	51
27	Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. <i>British Journal of Cancer</i> , 2013, 109, 147-153.	2.9	130
28	Trends and risk factors for severe perineal trauma during childbirth in New South Wales between 2000 and 2008: a population-based data study. <i>BMJ Open</i> , 2013, 3, e002824.	0.8	25
29	Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 595-605.	3.0	469
30	Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4701-4708.	1.8	72
31	Rates of obstetric intervention among low-risk women giving birth in private and public hospitals in NSW: a population-based descriptive study. <i>BMJ Open</i> , 2012, 2, e001723.	0.8	93
32	Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial. <i>Annals of Oncology</i> , 2012, 23, 2020-2027.	0.6	39
33	CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. <i>British Journal of Cancer</i> , 2012, 106, 633-637.	2.9	36
34	Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. <i>British Journal of Cancer</i> , 2012, 107, 588-591.	2.9	170
35	Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. <i>Annals of Oncology</i> , 2012, 23, 1185-1189.	0.6	57
36	Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. <i>Annals of Oncology</i> , 2011, 22, 2417-2423.	0.6	49

#	ARTICLE	IF	CITATIONS
37	Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1338-1342.	3.0	33
38	Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2011, 105, 1144-1150.	2.9	32
39	Carboplatin and paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2011, 105, 360-365.	2.9	28
40	Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 5052-5052.	0.8	8
41	Canadian Surgery Forum: Abstracts of presentations to the Annual Meetings of the Canadian Association of Bariatric Physicians and Surgeons, Canadian Association of General Surgeons, Canadian Association of Thoracic Surgeons, Canadian Hepato-Pancreato-Biliary Society, Canadian Society of Surgical Oncology, Canadian Society of Colon and Rectal Surgeons, London, Ont. Sept. 15-18, 2011. <i>Canadian Journal of Surgery</i> , 2011, 54, S57-S104.	0.5	0
42	Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. <i>Journal of Clinical Oncology</i> , 2010, 28, 3323-3329.	0.8	500
43	ABC; An AGITG trial of fixed dose rate (FDR) gemcitabine (gem) and cisplatin for patients (pts) with advanced biliary tract cancer (ABC). <i>Journal of Clinical Oncology</i> , 2007, 25, 15015-15015.	0.8	0
44	Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. <i>Blood</i> , 2006, 107, 4623-4627.	0.6	32
45	A Prospective Phase II Comparison of Stem Cell Source Using Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) Induction, Then High Dose Fludarabine, Busulfan (FLUBU) and Autologous (ASCT) or Allogeneic (AlloSCT) Hematopoietic Blood Stem Cell Transplantation for Mantle Cell (MCL) and Relapsed Low-Grade B-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2004, 104, 915-915.	0.6	0
46	A Low CD34+ Cell Dose Predicts Relapse and Death Early following Autologous Blood Stem Cell Transplantation. <i>Hematology</i> , 2001, 6, 19-27.	0.7	5
47	Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. <i>Bone Marrow Transplantation</i> , 1999, 23, 111-117.	1.3	46
48	High-level expression of secreted glycoproteins in transformed lepidopteran insect cells using a novel expression vector. <i>Journal of Biotechnology</i> , 1998, 60, 656-663.		86